Impax Laboratories Inc

Impax Laboratories — Technical Presentation (March 2011)

24 slides from Impax Laboratories's technical presentation, Mar 15, 2011

  1. Slide 1: Presentation of IPX066 ADVANCE-PD Phase III Study Results

    Presentation of IPX066 ADVANCE-PD Phase III Study Results March 15, 2011 ....Advancing CNS Treatment 1 Exhibit 99.2

  2. Slide 2: Safe Harbor Statement

    Safe Harbor Statement "Safe Harbor" Statement under the Private Securities Litigation Reform Act of 1995: To the extent any statements made in this presentation contain information that is not historical, these statements are forward-looking in nature and express the beliefs and expectations of mana

  3. Slide 3: Agenda

    Agenda Opening Remarks Dr. Larry Hsu: President & CEO, Impax Laboratories Background on IPX066 Development Michael Nestor: President, Impax Pharmaceuticals IPX066 Phase III ADVANCE-PD Study Results Dr. Suneel Gupta: Chief Scientific Officer, Impax Pharmaceuticals Key Opinion Leader Comments Dr. Robe

  4. Slide 4: Michael Nestor, President, Impax Pharmaceuticals

    Michael Nestor President, Impax Pharmaceuticals ....Advancing CNS Treatment 4

  5. Slide 5: Statistically Significant Top Line Results

    Statistically Significant Top Line Results IPX066 meets primary and secondary endpoints Significantly reduced percentage of "off time" Increased "on time" without troublesome dyskinesia Improved control of motor symptoms Generally well tolerated 5

  6. Slide 6: Parkinson's Disease Major Market Prevalence

    Parkinson's Disease Major Market Prevalence (in millions) Affects as many as 1-2% of persons aged 60 and older Afflicts more than 6 million people worldwide $3+ billion global market Symptoms are motor and non- motor in nature 6

  7. Slide 7: Naive PD Patient Phase III Study

    Naive PD Patient Phase III Study Phase III randomized, double-blind, placebo-controlled, fixed-dose, parallel arm study of 3 doses of IPX066 vs. placebo Enrolled 381 subjects with early PD Conducted under Special Protocol Assessment with FDA North America and Europe 30-week treatment duration Primar

  8. Slide 8: APEX-PD Phase III - Met Primary & Secondary Endpoints

    (p<0.0001 for all treatments) (p<0.0001 for both measures at all three dose levels) APEX-PD Phase III - Met Primary & Secondary Endpoints Significant clinical improvement Parkinson's Disease symptoms (UPDRS) Clinician & Patient Reported outcomes Clinical & Patient Global Impressions of Change (CGI,

  9. Slide 9: Advanced PD Patient Phase III Study

    Advanced PD Patient Phase III Study Phase III randomized, double-blind, active-control, parallel-group comparison of IPX066 vs. IR carbidopa-levodopa Enrolled 471 subjects with advanced PD North America and Europe 22-week treatment duration Primary endpoint: percentage of "off time" during waking ho

  10. Slide 10: IPX066: Development Status

    IPX066: Development Status Preclinical & POC Phase I Phase II Phase III NDA Submission Additional Studies Completed Completed Completed Completed 4Q 2011 Open Label Extension ADVANCE-PD & APEX-PD Advanced Patients (CD-LD + entacapone) ASCEND-PD 10

  11. Slide 11: Commercial Operations

    Commercial Operations Existing 66 sales reps building relationships with physicians Co-promotion agreement Estimated Expansion IPX066 Launch Additional 40 to 50 sales reps 11

  12. Slide 12: Collaboration with GlaxoSmithKline

    Collaboration with GlaxoSmithKline Joint Development and Commercialization of IPX066 Agreement reached in December 2010 Overview of agreement GSK acquires commercial rights outside of the US & Taiwan Impax received $11.5 million upfront payment Impax can receive additional milestones of up to $175 m

  13. Slide 13: Dr. Suneel Gupta, Chief Scientific Officer

    Dr. Suneel Gupta Chief Scientific Officer Impax Pharmaceuticals ....Advancing CNS Treatment 13

  14. Slide 14: Phase III Study Results IPX066 B09-02 (ADVANCE-PD)

    Phase III Study Results IPX066 B09-02 (ADVANCE-PD) A Study to Evaluate the Safety and Efficacy of IPX066 in Advanced Parkinson's Disease 14

  15. Slide 15: ADVANCE-PD: Phase III Study Design

    IR CD-LD, N = 192 D-30 V 5 Wk9 V 8 Wk22 V 1 Wk0 V 4 Wk7 V 2 Wk3 V 6 Wk12 V 7 Wk17 V 3 Wk5 ADVANCE-PD: Phase III Study Design ADVANCE-PD is a randomized, double-blind, parallel-group study of IPX066 versus IR CD-LD in advanced PD patients with motor fluctuations After screening, subjects are dose-adj

  16. Slide 16: Primary Endpoint: Comparison of Off Time as a Percentage of Waking Hours

    Primary Endpoint: Comparison of "Off Time" as a Percentage of Waking Hours p<0.0001 37% reduction 17% reduction IPX066 demonstrates a 37% improvement from baseline compared to 17% for IR CD-LD 16

  17. Slide 17: IPX066 Increases On Time Without an Increase in Dyskinesia

    -2.5 -2.0 -1.5 -1.0 -0.5 0.0 0.5 1.0 1.5 2.0 2.5 Change from Baseline (Hours) IPX066 IR CD-LD ^ Off Time p<0.0001 ^ On Time Without Troublesome Dyskinesia p<0.001 IPX066 Increases "On time" Without an Increase in Dyskinesia IPX066 "Off Time" improves 2.2 hours - "On Time" improves 1.9 hours 17

  18. Slide 18: IPX066 Treatment Leads to Improvement in PD Rating Scale

    IPX066 Treatment Leads to Improvement in PD Rating Scale IPX066 improved Unified Parkinson's Disease Rating Scale (UPDRS) during on state compared to IR CD-LD p<0.0001 Activities of Daily Living and Motor Symptom Control 18

  19. Slide 19: Changes in Clinical Global Impression and Other Patient Reported Endpoints

    Changes in Clinical Global Impression and Other Patient Reported Endpoints ANOVA: P < 0.0001 IPX066 improved Clinical Global Impression (CGI) of dose adjusted IR CD-LD patients 19

  20. Slide 20: Safety and Tolerability of IPX066 in ADVANCE-PD

    Safety and Tolerability of IPX066 in ADVANCE-PD IPX066 was generally well tolerated and had a similar frequency of overall adverse events as IR CD-LD One patient on each of the two treatment arms reported drug related serious adverse events during the double- blind treatment phase 20

  21. Slide 21: Summary of Adverse Events During The Double Blind Maintenance Phase

    Summary of Adverse Events During The Double Blind Maintenance Phase During The Double Blind Maintenance Phase During The Double Blind Maintenance Phase 21

  22. Slide 22: Study Conclusions

    Study Conclusions IPX066 demonstrates improved efficacy over IR CD-LD in all measured PD endpoints: "Off time" reduction, "On time" increase, Responder Analysis, and UPDRS IPX066 efficacy improvement is not associated with worsening of PD symptoms IPX066 significantly improved over IR CD-LD in secon

  23. Slide 23: Dr. Robert A. Hauser, University of South Florida

    Dr. Robert A. Hauser Professor of Neurology, Molecular Pharmacology, and Physiology and Director of the Parkinson's Disease & Movement Disorders Center at the University of South Florida ....Advancing CNS Treatment 23

  24. Slide 24: Question & Answer Session

    Question & Answer Session ....Advancing CNS Treatment 24

Impax Laboratories — Technical Presentation (March 2011) on 6ix